You searched for: inotropes (Engelska - Maltesiska)

requiring inotropes
Ħtieġa ta’ inotropes

the effects of medicinal products with similar properties such as the inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
l-effetti ta’ prodotti mediċinali bi kwalitajiet simili bħall-inotropi milrinone, enoximone, amrinone, olprinone u cilostazol jistgħu jiħraxu permezz ta’ anagrelide.

best standard care includes adequate antibiotics, source control and supportive treatment (fluids, inotropes, vasopressors and support of failing organs, as required).
il-kura msemmija kienet tinkludi antibijotiċi adegwati, kontroll tal-kawża tas-sepsis u kura ta’ għajnuna (fluwidi, inotropi, vażopressuri u għajnuna għall-organi li ma kinux jiffunzjonaw tajjeb, kif meħtieġ).

the effects of medicinal products with similar properties such as the inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide. • in vivo interaction studies in humans have demonstrated that anagrelide does not affect the pharmacokinetic properties of digoxin or warfarin. • at the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide may theoretically potentiate the effects of other medicinal products that inhibit or modify platelet function e. g. acetylsalicylic acid. • a clinical interaction study performed in healthy subjects showed that co-administration of repeat-dose anagrelide 1mg once daily and acetylsalicylic acid 75mg once daily may enhance the anti-platelet aggregation effects of each drug compared with administration of acetylsalicylic acid alone.
l- effetti ta ’ prodotti mediċinali bi kwalitajiet simili bħall- inotropi milrinone, enoximone, amrinone, olprinone u cilostazol jistgħu jiħraxu permezz ta ’ anagrelide. • studji ta ’ interazzjonijiet in vivo fil- bnedmin urew li anagrelide ma jaffettwax il- kwalitajiet farmakokinetiċi ta ’ digoxin jew warfarin. • fid- dożi rakkomandati għal użu fit- trattament ta ’ tromboċitemja essenzjali, anagrelide jista ’ teoritikament iqawwi l- effetti ta ’ prodotti mediċinali oħra li jimpedixxu jew jimmodifikaw il - funzjoni tal- plejtlets eż. acetylsalicylic acid. • studju dwar interazzjoni klinika li sar fuq persuni b’ saħħithom wera li l- għoti flimkien ta ’ doża ripetuta ta ’ anagrelide 1mg darba kuljum u acetylsalicylic acid 75mg darba kuljum jista ’ jtejjeb l- effetti tal- aggregazzjoni tal- anti- plejtlits ta ’ kull mediċina meta mqabbel mal- għoti ta ’ acetylsalicylic acid waħdu.